li001

Multi-Omics Study Identifies Key Genetic Drivers and Therapeutic Targets in Angioimmunoblastic T-Cell Lymphoma

Rare Cancers /

A large multi-omics study of Angioimmunoblastic T-cell lymphoma (AITL) analyzed 174 patient cases and used patient-derived mouse models to better understand this aggressive blood cancer. Researchers found that the disease is driven mainly by genetic changes affecting epigenetic regulation, T-cell receptor signaling, and the PI3K/AKT pathway. The most frequent mutations included TET2 (81%), DNMT3A (31%), and […]

Multi-Omics Study Identifies Key Genetic Drivers and Therapeutic Targets in Angioimmunoblastic T-Cell Lymphoma Read More »

Metabolic Therapy Improves Fertility-Sparing Treatment in Endometrial Cancer

Targeted Therapy /

A study shows that combining anti-estrogen therapy with metabolic-targeted treatments—like metformin for diabetes or insulin resistance, statins for dyslipidemia, and calcium channel blockers for hypertension—can enhance fertility-preserving outcomes in endometrial cancer (EC) and endometrial atypical hyperplasia (EAH). Among 285 patients treated, 77% achieved complete response within six months, and pregnancy and live birth rates reached 38%

Metabolic Therapy Improves Fertility-Sparing Treatment in Endometrial Cancer Read More »

Durvalumab Plus Tremelimumab Improves Survival but Impacts Quality of Life in Kidney Cancer

Treatment /

The Phase 3 RAMPART Trial studied the combination of Durvalumab and Tremelimumab in patients with kidney cancer who had undergone surgery. The treatment helped prevent cancer from returning, with three-year disease-free survival at 81% compared to 73% for patients under standard monitoring, reducing the risk of recurrence or death by 35%. However, the therapy also

Durvalumab Plus Tremelimumab Improves Survival but Impacts Quality of Life in Kidney Cancer Read More »

ResearchersCreates Digital Immune Atlas to Guide Pancreatic Cancer Treatment

Immunotherapy /

Researchers have created a first-of-its-kind Digital Immune Atlas to tackle pancreatic cancer, a disease long resistant to immunotherapy. By analyzing over a decade of clinical trial samples from 64 patients, the team mapped how the immune system responds to treatments like vaccines (GVAX, CRS-207) and checkpoint inhibitors (anti-PD-1, anti-CTLA-4). The atlas revealed that even when

ResearchersCreates Digital Immune Atlas to Guide Pancreatic Cancer Treatment Read More »

FDA Approves Pylarify TruVu for High-Precision Prostate Cancer Imaging

Precision Medicine /

The FDA has approved Pylarify TruVu (piflufolastat F 18), a new PET imaging agent that helps detect prostate cancer that has spread or returned. Pylarify TruVu targets the Prostate-Specific Membrane Antigen (PSMA) on cancer cells, making them visible on a PET/CT scan. The approval covers two groups of men: those with high-risk prostate cancer before

FDA Approves Pylarify TruVu for High-Precision Prostate Cancer Imaging Read More »

AI and Digital Pathology Improve Risk Assessment in Early Breast Cancer

Diagnostics /

Researchers discussed how artificial intelligence (AI) and digital pathology are improving risk assessment in HR-positive, HER2-negative early breast cancer. By combining clinical factors with AI analysis of digital slides and gene expression, doctors can now identify patients who appear high-risk clinically but are actually low-risk biologically. AI helps predict both prognosis and treatment response. For

AI and Digital Pathology Improve Risk Assessment in Early Breast Cancer Read More »

Dato-DXd Plus Durvalumab Shows Strong Results in Metastatic Triple-Negative Breast Cancer

Treatment /

Researchers reported encouraging results from the BEGONIA Trial, which tested a combination of the antibody-drug conjugate Dato-DXd and the immunotherapy Durvalumab in patients with metastatic triple-negative breast cancer (TNBC). The treatment showed high effectiveness, with nearly 80% of patients experiencing tumor shrinkage. Objective response rates were 79% in one group and 81.8% in another, and

Dato-DXd Plus Durvalumab Shows Strong Results in Metastatic Triple-Negative Breast Cancer Read More »

Five-Day Radiation Therapy Shows Promise for Shrinking Advanced Breast Tumors

Treatment /

Researchers studied a faster form of radiation therapy called ultra-hypofractionated radiotherapy for patients with advanced breast cancer. This approach delivers a higher radiation dose in fewer treatment sessions. In the study, patients received 25 Gy of radiation in only five sessions to the breast and nearby lymph nodes. Most of the 45 patients in the

Five-Day Radiation Therapy Shows Promise for Shrinking Advanced Breast Tumors Read More »

Blood Test May Help Some Bladder Cancer Patients Avoid Bladder Removal Surgery

Molecular Oncology /

Researchers presented a study at the ASCO Genitourinary Cancers Symposium 2026 examining whether circulating tumor DNA (ctDNA) can help guide treatment decisions for patients with muscle-invasive bladder cancer. The research was part of the RETAIN-2 trial and focused on patients who received chemoimmunotherapy with Nivolumab instead of immediately undergoing bladder removal surgery (cystectomy). The study

Blood Test May Help Some Bladder Cancer Patients Avoid Bladder Removal Surgery Read More »

TROP2-Targeted ADCs Emerging as First-Line Therapy for Metastatic Triple-Negative Breast Cancer

Treatment /

A new approach is changing how metastatic triple-negative breast cancer (mTNBC) is treated. Experts are now focusing on TROP2-targeted antibody-drug conjugates (ADCs) as a first-line therapy instead of traditional chemotherapy. Recent clinical studies suggest these targeted drugs can help patients live longer and delay disease progression. Three major Phase 3 trials reported in 2025 support

TROP2-Targeted ADCs Emerging as First-Line Therapy for Metastatic Triple-Negative Breast Cancer Read More »